novo nordisk oral glp-1 Details of failed studies cast pall on Nordisk's as Alzheimer's treatment PRESS: EU approval makes Novo
Description
Why diabetes drugs are driving tech-like returns in healthcare.
This systematic ...
These assets aim to move beyond the current weekly injection paradigm, signalling a future where extended dosing intervals could become central to maintenance strategies [16].
GLP-1 weight-loss drugs like semaglutide have taken the world by storm, but some studies have raised concerns about side effects, including kidney injury and skeletal muscle wastage
Learn what Wegovy is, how it works to help you, and its potential side effects and interactions.
This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide).
